Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMark A. Schroeder

Discussion

Loading...

Member takes

Overview

Prospective trial shows enhanced premedication improves stem cell mobilization outcomes in multiple myeloma.

Key Points

  • The study aims to assess the efficacy of motixafortide plus G-CSF for hematopoietic stem cell mobilization after quad induction therapy in multiple myeloma.
  • Prospective, open-label trial with two arms comparing standard and early dosing of motixafortide.
  • Patients received leukocytapheresis procedures to assess mobilization outcomes.
  • Enhanced premedication regimen evaluated to reduce adverse effects during the mobilization process.
  • 80% of patients collected ≥6×106 CD34+ cells/kg and all collected ≥2×106 CD34+ cells/kg in ≤2 leukocytapheresis procedures.
  • Median peak peripheral blood hematopoietic stem cell mobilization was 62.5 CD34+ cells/μl, varying between arms.
  • Enhanced premeds led to a lower rate of injection site and systemic reactions compared to historical controls.

Cite This Study

Mark A. Schroeder (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db25https://doi.org/10.1182/blood-2025-5957
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved hematopoietic stem cell mobilization for gene therapy using single agent motixafortide in sickle cell disease2025
  2. 2Efficacy of motixafortide plus G-CSF versus plerixafor plus G-CSF for stem cell mobilization and collection in multiple myeloma: A single-center comparative analysis and interim Results from a prospective study in poor mobilizers2025
  3. 3Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study2025 · 2 citations
  4. 4Comparative Efficacy of Autologous Hematopoietic Stem Cell Mobilization Regimens in Multiple Myeloma Patients2024
  5. 5Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial2025